Document is current
Any future updates will be listed below
-
Authors
Farrell, Clíona
Buhidma, Yazead
Mumford, Paige
Heywood, Wendy E.
Hällqvist, Jenny
Flores-Aguilar, Lisi
Andrews, Elizabeth J.
Rahimzadah, Negin
Taso, Orjona Stella
Doran, Eric
Swarup, Vivek
Head, Elizabeth
Lashley, Tammaryn
Mills, Kevin
Toomey, Christina E.
Wiseman, Frances K.
-
Funding
Funding for this research was provided by:
Alzheimer's Society (AS-PhD-19a-007, AS-PhD-19a-007)
UK Dementia Research Institute (UKDRI-1211, UKDRI-1014, UKDRI-1014, UKDRI-1014)
National Institute on Aging (U19AG068054, U19AG068054, U19AG068054, U19AG068054)
Alzheimer’s Association (23AARFD-1022715)
Fondation Jérôme Lejeune (JLF-5694682)
Alzheimer’s Research UK (ARUK-SRF2018A-001)
Rosetrees Trust (MB2020\100003)
- License Information
-
More Information
Article History
Received: 19 February 2025
Revised: 25 April 2025
Accepted: 1 May 2025
First Online: 19 May 2025
Declarations
:
: The authors declare that they have no competing interests. F.K.W. has undertaken for fee consultancy for Alnylam Pharmaceuticals.
: Human tissue: The use of human tissues in this study was in accordance with the UK Human Tissue Act (2004). Samples for the discovery cohort and validation cohort A were supplied, anonymized by the Newcastle Brain and Tissue Resource (NBTR), Newcastle University, Newcastle, UK and the South West Dementia Brain Bank (SWDBB), Bristol University, UK, and had full research consent (REC 19/NE/0008) and (REC 18/SW/0029). This work was carried out under NBTR and SWDBB’s NHS REC Research Tissue Bank ethical approval. Validation cohort B, studied at UCI, were obtained through IRB approved protocols and consent.
: Not applicable.
